Literature DB >> 23660685

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.

K M Bernot1, R F Siebenaler, S P Whitman, N A Zorko, G G Marcucci, R Santhanam, E H Ahmed, M Ngangana, K K McConnell, J S Nemer, D L Brook, S K Kulp, C S Chen, D Frankhouser, P Yan, R Bundschuh, X Zhang, A M Dorrance, K E Dickerson, D Jarjoura, W Blum, G Marcucci, M A Caligiuri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23660685      PMCID： PMC3864138          DOI： 10.1038/leu.2013.147

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

Authors:  William Blum; Rebecca B Klisovic; Bjoern Hackanson; Zhongfa Liu; Shujun Liu; Hollie Devine; Tamara Vukosavljevic; Lenguyen Huynh; Gerard Lozanski; Cheryl Kefauver; Christoph Plass; Steven M Devine; Nyla A Heerema; Anthony Murgo; Kenneth K Chan; Michael R Grever; John C Byrd; Guido Marcucci
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

2.  Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.

Authors:  S Schnittger; U Kinkelin; C Schoch; A Heinecke; D Haase; T Haferlach; T Büchner; B Wörmann; W Hiddemann; F Griesinger
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

3.  The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia.

Authors:  M P Strout; G Marcucci; C D Bloomfield; M A Caligiuri
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

4.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Authors:  Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'brien; Elihu Estey; Carlos Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

5.  Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

Authors:  M A Caligiuri; M P Strout; D Lawrence; D C Arthur; M R Baer; F Yu; S Knuutila; K Mrózek; A R Oberkircher; G Marcucci; A de la Chapelle; E Elonen; A W Block; P N Rao; G P Herzig; B L Powell; T Ruutu; C A Schiffer; C D Bloomfield
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

6.  Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.

Authors:  Qiang Lu; Da-Sheng Wang; Chang-Shi Chen; Yuan-Dong Hu; Ching-Shih Chen
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

7.  DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.

Authors:  Susan P Whitman; Björn Hackanson; Sandya Liyanarachchi; Shujun Liu; Laura J Rush; Kati Maharry; Dean Margeson; Ramana Davuluri; Jing Wen; Tatiana Witte; Li Yu; Chunhui Liu; Clara D Bloomfield; Guido Marcucci; Christoph Plass; Michael A Caligiuri
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

8.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

Authors:  Konstanze Döhner; Karen Tobis; Regina Ulrich; Stefan Fröhling; Axel Benner; Richard F Schlenk; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

9.  Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.

Authors:  A Mims; A R Walker; X Huang; J Sun; H Wang; R Santhanam; A M Dorrance; C Walker; P Hoellerbauer; S S Tarighat; K K Chan; R B Klisovic; D Perrotti; M A Caligiuri; J C Byrd; C-S Chen; L James Lee; S Jacob; K Mrózek; C D Bloomfield; W Blum; R Garzon; S Schwind; G Marcucci
Journal:  Leukemia       Date:  2012-11-26       Impact factor: 11.528

10.  Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Authors:  Susan P Whitman; Amy S Ruppert; Guido Marcucci; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Tamara Vukosavljevic; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Clara D Bloomfield
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113
View more
  8 in total

Review 1.  Hypoxia-inducible factors in cancer stem cells and inflammation.

Authors:  Gong Peng; Yang Liu
Journal:  Trends Pharmacol Sci       Date:  2015-04-06       Impact factor: 14.819

Review 2.  Origins of aberrant DNA methylation in acute myeloid leukemia.

Authors:  T Schoofs; W E Berdel; C Müller-Tidow
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

3.  Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.

Authors:  Yin Wang; Yan Liu; Fei Tang; Kelsie M Bernot; Reuven Schore; Guido Marcucci; Michael A Caligiuri; Pan Zheng; Yang Liu
Journal:  Blood       Date:  2014-07-03       Impact factor: 22.113

4.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

5.  Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.

Authors:  Kelsie M Bernot; John S Nemer; Ramasamy Santhanam; Shujun Liu; Nicholas A Zorko; Susan P Whitman; Kathryn E Dickerson; Mengzi Zhang; Xiaojuan Yang; Kathleen K McConnell; Elshafa H Ahmed; Maura R Muñoz; Ronald F Siebenaler; Gabriel G Marcucci; Bethany L Mundy-Bosse; Daniel L Brook; Sabrina Garman; Adrienne M Dorrance; Xiaoli Zhang; Jianying Zhang; Robert J Lee; William Blum; Michael A Caligiuri; Guido Marcucci
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

6.  High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.

Authors:  Hsiao-Wen Kao; D Cherng Liang; Ming-Chung Kuo; Jin-Hou Wu; Po Dunn; Po-Nan Wang; Tung-Liang Lin; Yu-Shu Shih; Sung-Tzu Liang; Tung-Huei Lin; Chen-Yu Lai; Chun-Hui Lin; Lee-Yung Shih
Journal:  Oncotarget       Date:  2015-10-20

7.  A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

Authors:  Alice S Mims; Anjali Mishra; Shelley Orwick; James Blachly; Rebecca B Klisovic; Ramiro Garzon; Alison R Walker; Steven M Devine; Katherine J Walsh; Sumithira Vasu; Susan Whitman; Guido Marcucci; Daniel Jones; Nyla A Heerema; Gerard Lozanski; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Richard Piekarz; Michael R Grever; William Blum
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

8.  MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.

Authors:  Zhipeng He; Bixin Wang; Lili Chen; Yiping Huang; Huixian Wang; Mengting Yang; Xueting Xiao; Yanhong Lu; Jiaying Chen; Yong Wu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.